Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ATS Medical, a manufacturer and marketer of cardiac surgery products and services, has announced that the Australian Therapeutic Goods Administration has granted approval for commercialization of the ATS 3f aortic bioprosthesis.
Subscribe to our email newsletter
The ATS 3f aortic bioprosthesis is a next generation stentless pericardial aortic tissue valve.
According to the company, the primary benefit of the ATS 3f aortic bioprosthesis is its tubular design that restores continuity between the annulus and the sinotubular junction. By restoring this continuity, the ATS 3f aortic bioprosthesis is the only aortic valve that preserves the aortic sinuses and restores native valve stress distribution and physiologic blood flow, the company said. This valve design reportedly provides surgeons and patients with a potentially more durable solution to aortic valve replacement.